CCR2 antagonists have been found to suppress hepatocellular carcinoma growth [65], reduce lung metastasis from LLC tumours [66] and liver metastases from colorectal [67] or breast cancer xenografts [68] in animal models. Here, CCR2 is linked to neoplasm.